drugset / Trial / NCT02011594
Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
There have been reports suggesting that anti-epidermal growth factor antibody nimotuzumab is advantageous for advanced esophageal cancer patients in combination with chemotherapy or radiotherapy. However, whether maintenance therapy of nimotuzumab provides benefit to advanced esophageal cancer patients is not known.
Timeline
- Start
- 2014-01
- Primary completion
- 2015-01
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nimotuzumab | Monoclonal antibody | 400 mg | Intravenous |